NeoADAPTA Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics

This clinical trial is focusing on patients diagnosed with stage 2 and 3 triple-negative breast cancer. The study aims to explore a treatment approach that uses a combination of chemotherapy drugs paclitaxel, carboplatin, and pembrolizumab, followed by an evaluation of how the cancer responds early on through imaging and biomarker analysis. This kind of cancer is known for being aggressive and difficult to treat, so finding effective treatment strategies is crucial. By adapting the treatment based on early detection of response, the study hopes to improve the outcomes for people facing this challenging diagnosis. Participants in this study begin with initial tests, including bloodwork, MRI, and PET scans, to establish a baseline. They then receive the treatment drugs through an intravenous infusion. After the first cycle, the same tests are repeated to monitor changes. If the cancer appears to respond well, the patient proceeds to surgery. If not, additional treatments are given before surgery. Throughout the study, periodic blood samples are collected to track cancer DNA changes. After surgery, depending on the cancer's response, further treatment options are considered, which might include additional medication. This approach aims to tailor treatment to each individual's cancer response, potentially increasing the effectiveness of the therapy.